Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.

MLA

Magrin, Elisa, et al. “Long-Term Outcomes of Lentiviral Gene Therapy for the β-Hemoglobinopathies: The HGB-205 Trial.” Nature Medicine, vol. 28, no. 1, Jan. 2022, pp. 81–88. EBSCOhost, https://doi.org/10.1038/s41591-021-01650-w.

APA

Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., Gabrion, A., Roudaut, C., Marouene, J., Lefrere, F., Diana, J.-S., Denis, A., Neven, B., Funck-Brentano, I., Negre, O., Renolleau, S., Brousse, V., Kiger, L., Touzot, F., … Cavazzana, M. (2022). Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Nature Medicine, 28(1), 81–88. https://doi.org/10.1038/s41591-021-01650-w

Chicago

Magrin, Elisa, Michaela Semeraro, Nicolas Hebert, Laure Joseph, Alessandra Magnani, Anne Chalumeau, Aurélie Gabrion, et al. 2022. “Long-Term Outcomes of Lentiviral Gene Therapy for the β-Hemoglobinopathies: The HGB-205 Trial.” Nature Medicine 28 (1): 81–88. doi:10.1038/s41591-021-01650-w.